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Introduction: Non-invasive strategies to predict variceal from non-variceal bleeding will be highly beneficial 
for preemptive management of Upper Gastrointestinal Bleeding (UGIB). This study aimed to assess the role 
of aspartate aminotransferase (AST) to platelet ratio index (APRI) as a non-invasive predictor of variceal 
etiology of UGIB. Methods: This was a retrospective descriptive study conducted at Endoscopy Department 
of Dhulikhel Hospital between January 2017 and December 2019 in patients presenting with acute UGIB. 
We assessed the diagnostic utility of the APRI score relative to other objective measures by Area Under the 
Receiver Operating Characteristic (AUROC) curve analysis. Results: A total of 158 patients with history 
of UGIB were included in the study. There were total 123 males (77.8%) and the mean age of the patients 
was 50.3±16.1 years. The APRI score performed well in predicting a variceal etiology of acute UGIB, with 
AUROC 0.9. When APRI was used at cut-off of 1.3, it had a sensitivity of 84.1% and specificity of 76.8%, 
a positive predictive value of 70.7% and a negative predictive value of 89.9% while predicting variceal 
etiology of UGIB at presentation. The relative risk of varices at an APRI cut-off of 1.3 is 17.5 with a p-value 
of <0.0001. Conclusion: The present study highlighted that APRI score can be used as an objective metric 
that helps to predict a variceal etiology of acute UGIB.
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INTRODUCTION:
 Cirrhosis is characterized by fibrosis and 
the conversion of normal liver architecture into 
structurally abnormal nodules.[1] The prevalence of 
esophageal varices (EV) in cirrhotics is between 60 
and 80%.[2] Mortality rate due to variceal bleeding 
episode is about 10-20% and the life expectancy is 
around 63%.[3,4] 
 Till date proton pump inhibitor remains the 
mainstay of treatment for non-variceal bleeding.
[5] In contrast, for variceal hemorrhage, medical 
management mainly involves intravenous vasoactive 
therapy (octreotide and terlipressin), intravenous 
antibiotics (third generation cephalosporins) and 
guarded blood transfusion.[6] Evidence also 
supports benefits of early endoscopy for variceal 
bleed but not as much for non-variceal bleed.[7,8]
 Aspartate aminotransferase to Platelet Ratio 
Index (APRI), was initially introduced as a measure 
to quantify fibrosis of the liver in patients with 
Hepatitis C, however today it has been established 
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as a marker of cirrhosis and portal hypertension 
in many studies.[9,10] APRI can hence also act 
as a good non-invasive method for the screening 
of variceal bleeding in acute setting of Upper 
Gastrointestinal Bleeding (UGIB) and direct us 
towards early management before definite diagnosis 
is established with endoscopy.
METHODS:
 This was a hospital based retrospective 
descriptive study conducted from January 2017 
to December 2019. All patients presenting with 
features suggestive of UGIB in the out-patient and 
emergency department (ED) were included in the 
study. The patients with no documented complaints 
of overt gastrointestinal (GI) bleeding, in whom 
endoscopy was not performed during admission, 
and with incomplete medical records were excluded 
from the study. Questionnaire included variables 
such as age, gender, ethnicity, history of malena, 
hematemesis, hematochezia, cirrhosis / portal 
hypertension, endoscopic diagnosis, biochemical 
levels of aspartate aminotransferase (AST) , alanine 
aminotransferase (ALT) and platelet count. Patients 
who presented with repeated UGIB due to the 
same underlying etiology were included only once. 
Prior ethical approval was taken from Institutional 
Review Committee (IRC) of Dhulikhel Hospital, 
Kathmandu University hospital (IRB: 291/19). 
APRI was calculated using first available ED data as 
following: [9]
APRI = [AST level / AST-upper limit X platelet 
count (109/L)] X 100
 Statistical analysis was performed using 
Statistical Package for the Social Sciences (SPSSTM) 
20.0 software for windows. We used Area Under 
the Receiver Operating Characteristics Curve 
(AUROC) as the measure of relative diagnostic 
accuracy in comparing tests. Deviations from the 
null hypothesis with a probability of p<0.05 were 
considered significant.
RESULTS:
 There were 283 presentations with UGIB 
out of which 158 cases met the inclusion criteria 
and were included in the study. The mean age of the 
study population was 50.3±16.1 years, with a range 
of 4-86 years. The age group 40-60 years included 
76 (47.8%) patients. There was a male predominance 
with 123 (77.8%) patients. The predominant ethnic 
groups included Tamang (n=44, 27.4%), Newar 
(n=42, 26.6%) and Brahmin/Chettri (n=37, 23.4%). 
 
Table 1. Clinical Variables of the Study Population 
(N=158).
Clinical variables Category Frequency 
(%)
Malena Absent 50 (31.6)
Present 108 (68.4)
Hematemesis Present 133 (84.2)
Absent 25 (15.8)
Hematochezia Absent 151 (95.6)
Present 7 (4.4)
History of Cirrhosis /
Portal Hypertension
Absent 108 (68.4)
Present  50 (31.6)
Endoscopic diagnosis Variceal 63 (39.9)
Non-variceal 95 (60.1)
ALT (IU/L) ≤56 101 (63.9)
>56 57 (36.1)
AST (IU/L) ≤40 55 (34.8)
>40 103 (65.2)





Table 2. Causes of Non Variceal Bleeding  (N=95).
Causes Frequency 
(%)
Gastric Ulcer 22 (23.2)
Duodenal Ulcer 21 (21.1)
Gastroduodenitis 19 (20)
Malory Weiss Tear 13 (13.7)
Esophagitis/esophageal Ulcer 8 (8.4)
Gastric Carcinoma 4 (4.2)
GAVE (Gastric Antral Vascular 
Ectasia)
3 (3.2)
Polyp bleed 3 (3.2)
Deulafoy’s Lesion 2 (2.1)
Total 95 (100)
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 Table 1 represents the clinical variables 
among the study population. Upon review of all 
available data including endoscopy reports, we 
classified 63 (39.9%) cases as variceal UGIB and 
95 (60.1%) as non-variceal UGIB. Of the patients 
with clinical features of chronic liver disease (CLD), 
40 (80%) had variceal bleeding, nine (18%) had 
non-variceal bleeding, and one (2%) had unknown 
source of bleed. In contrast, among patients without 
clinical features of CLD 23 (21.3%) had variceal 
bleeding, 79 (73.1%) had non-variceal bleeding, and 
six (5.6%) had unknown source of bleed. Table 2 
represents the causes of non-variceal bleeding.
 We plotted sensitivity versus specificity over 
a range of possible cut-off values for each score to 
generate a receiver operating characteristic (ROC) 
curves comparing the performance of APRI score 
(Table 3). When APRI was used at cut-off of 1.3, it 
had a sensitivity of 84.1% and specificity of 76.8%, 
a positive predictive value (PPV) of 70.7% and a 
negative predictive value (NPV) of 89.9% while 
predicting variceal etiology of UGIB at presentation. 
The relative risk of varices at an APRI cut-off of 1.3 
is 17.5 with a p-value of <0.0001 (Table 4).
Table 4. Relative risk at APRI score of 1.3.
Cut-
off
Endoscopic findings RR p value
Variceal Non- 
variceal
>1.2 53 22 17.5 <0.0001
<=1.2 10 73
Figure 1. ROC curve (AUC=0.90). 
Other cutoff points were also tested, but none of 
them could reach a significantly better positive and 
negative predictive value. Considering all patients 
presenting with apparent UGIB, we found that APRI 
had good performance in discriminating between 
variceal versus non-variceal UGIB with AUROC 
of 0.9 (Figure 1). An ideal test is associated with 
AUROC of 1.0 and with an AUROC of 0.9 the APRI 
score would be considered to have very good to 
excellent performance.[11]
DISCUSSION:
 Variceal bleeding is one of the most dramatic 
and fatal complications of cirrhosis. The prevalence 
of esophageal varices (EV) in cirrhotics is highly 
Table 3. Sensitivity, Specificity, PPV and NPV of APRI Score At Different Cut Offs Levels (* FN = False 
Negative; TN = True Negative; TP = True Positive; FP = False Positive).




1(FN) 55 (TN) 98.5 57 60.7 98.2
62 (TP) 40 (FP)
<=1
>1












12 74 80.9 77.9 70.8 86.0
51 21
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variable.[2] Even in known cirrhotic patients 
presenting with UGIB, non variceal etiology of 
bleeding has to be ruled out because of difference 
in their management. For variceal bleeding evidence 
suggests early endoscopy along with intravenous 
vasoactive drugs, antibiotics and guarded blood 
transfusion.[6,7,8] Whereas proton pump inhibitors 
remain the mainstay of treatment for non-variceal 
bleeding.[5] Hence, the prediction of variceal 
bleeding in the Emergency Department (ED) will 
help in the management of patients with UGIB before 
the definite diagnostic and therapeutic endoscopy is 
performed.
 The APRI score is easily calculated from 
routinely collected laboratory data available early 
in the ED setting. Shaheen et. al. reported that in 
patients with chronic hepatitis C, APRI score < 0.5 
had a negative predictive value (NPV) of 72%, while 
the APRI score >1.5 had a positive predictive value 
(PPV) of 87% for prediction of fibrosis.[12]Wai CT et 
al. in their study had a conclusion that APRI score can 
predict accurately significant fibrosis and cirrhosis 
in 51% and 81% respectively, potentially avoiding 
the need for liver biopsies in patients.[9] The first 
authors to raise the hypothesis that APRI could be 
related to the presence of EV were Sanyal et al.[13] 
They examined 1,016 patients with compensated 
liver cirrhosis and reported a correlation between 
APRI score and the presence of esophageal varices 
(p=0.01). Later Castéra, et al. proposed the cutoff of 
1.3 for APRI as a predictor of EV.[14]
While plotting the sensitivity, specificity, PPV and 
NPV of APRI score at different cut off levels, we also 
found that cut-off at 1.3 had a very good NPV. (Table 
3) For a non-invasive test like APRI to be considered 
helpful in the studied context, it should have a great 
negative predictive value, as misdiagnosing variceal 
bleeding as not having EV is a risk for major 
complication. The mortality of variceal bleeding in 
different studies is around 15%.[15] Clinical signs 
and symptoms of cirrhosis prompting suspicion for a 
variceal etiology can be unreliable.[16] In this study, 
we found that the APRI score performed well as 
measured by ROC analysis with an AUROC of 0.9 in 
predicting a variceal etiology of acute UGIB. Thus, 
the APRI score represents an objective measure that 
could be used to guide early management decisions 
for UGIB patients while awaiting endoscopy.
A study by Civan et al., concluded that a clinical 
decision rule based on APRI improves adherence to 
published guidelines on the management of acute 
variceal bleeding using the prophylactic antibiotics 
and somatostatin analogues.[17]  The APRI cutoff 
value of 0.4 was used in their clinical decision rule 
which is lower than the cutoffs reported in other 
studies. The reason for low cut-off value of APRI 
used in this study according to the authors was their 
reflection of their prioritization of sensitivity over 
specificity, and led them to design a clinical decision 
rule with a positive predictive value of 0.33 and 
negative predictive value of 0.98.
 In this study, at APRI cut-off of 0.4 we had 
PPV of 0.61 and NPV of 0.98 that is an increased 
NPV compared to APRI cut-off at 1.3. Low PPV 
will increase the number of patients without varices 
receiving antibiotics and somatostatin analogues. 
Octreotide is very well tolerated and a brief course 
in patients without varices will not cause increased 
morbidity.[18] Unnecessary courses of antibiotics 
however might cause an increase in Clostridium 
difficile infection. Both these factors also will 
increase the cost of treatment which has to be taken 
into account especially in developing country like 
ours. At APRI cut-off of 1.3 however there is a 
good sensitivity and specificity without significantly 
compromising either of the PPV and NPV values 
(Table 3).
CONCLUSION:
 The present study found that the APRI score 
could serve as a useful objective measure to identify 
variceal etiology of bleeding in UGIB patients. 
Patients presenting with apparent acute UGIB with 
APRI score of more than or equal to 1.3 can be 
managed in the line of variceal bleed before definite 
endoscopic diagnosis.
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